Tanmoy Arif Mohammad, Ahmed Asm Nawshad Uddin, Arumugam Rajesh, Hossain Belal, Marzan Mahfuza, Saha Shampa, Arifeen Shams El, Baqui Abdullah H, Black Robert E, Kang Gagandeep, Saha Samir Kumar
Child Health Research Foundation, Department of Microbiology, Dhaka Shishu Hospital, Dhaka, Bangladesh.
Department of Pediatrics, Dhaka Shishu Hospital, Bangladesh Institute of Child Health, Dhaka, Bangladesh.
PLoS One. 2016 Apr 20;11(4):e0153582. doi: 10.1371/journal.pone.0153582. eCollection 2016.
The World Health Organization (WHO) currently coordinates rotavirus diarrhea and invasive bacterial disease (IBD) surveillance at 178 sentinel sites in 60 countries. However, only 78 sites participate in both surveillance systems using a common sentinel site. Here, we explored the feasibility of extending a WHO-IBD surveillance platform to generate data on the burden of rotaviral diarrhea and its epidemiological characteristics to prepare the countries to measure the impact of rotaviral vaccine. A six-month (July to December, 2012) surveillance, managed by IBD team, collected stool samples and clinical data from under-five children with acute watery diarrhea at an IBD sentinel site. Samples were tested for rotavirus antigen by ELISA and genotyped by PCR at the regional reference laboratory (RRL). Specimens were collected from 79% (n=297) of eligible cases (n=375); 100% of which were tested for rotavirus by ELISA and 54% (159/297) of them were positive. At RRL, all the cases were confirmed by PCR and genotyped (99%; 158/159). The typing results revealed the predominance of G12 (40%; 64/159) genotype, followed by G1 (31%; 50/159) and G9 (19%; 31/159). All in all, this exploratory surveillance collected the desired demographic and epidemiological data and achieved almost all the benchmark indicators of WHO, starting from enrollment number to quality assurance through a number of case detection, collection, and testing of specimens and genotyping of strains at RRL. The success of this WHO-IBD site in achieving these benchmark indicators of WHO can be used by WHO as a proof-of-concept for considering integration of rotavirus surveillance with WHO-IBD platforms, specifically in countries with well performing IBD site and no ongoing rotavirus surveillance.
世界卫生组织(WHO)目前在60个国家的178个哨点协调轮状病毒腹泻和侵袭性细菌性疾病(IBD)监测。然而,只有78个哨点使用共同的哨点参与这两种监测系统。在此,我们探讨了扩展WHO-IBD监测平台以生成轮状病毒腹泻负担及其流行病学特征数据的可行性,以便让各国做好准备来衡量轮状病毒疫苗的影响。由IBD团队管理的为期六个月(2012年7月至12月)的监测,在一个IBD哨点收集了五岁以下急性水样腹泻儿童的粪便样本和临床数据。样本通过酶联免疫吸附测定(ELISA)检测轮状病毒抗原,并在区域参考实验室(RRL)通过聚合酶链反应(PCR)进行基因分型。从79%(n = 297)的符合条件病例(n = 375)中采集了样本;其中100%通过ELISA检测轮状病毒,54%(159/297)呈阳性。在RRL,所有病例均通过PCR确认并进行基因分型(99%;158/159)。分型结果显示G12基因型占主导(40%;64/159),其次是G1(31%;50/159)和G9(19%;31/159)。总而言之,这次探索性监测收集到了所需的人口统计学和流行病学数据,并几乎达到了WHO的所有基准指标,从入组人数到质量保证,通过一系列病例检测、样本收集和检测以及RRL菌株基因分型。WHO这个IBD哨点在实现WHO这些基准指标方面的成功,可被WHO用作将轮状病毒监测与WHO-IBD平台整合的概念验证,特别是在IBD哨点运行良好且没有正在进行的轮状病毒监测的国家。